Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
ConditionHypertriglyceridemia
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorMarea Therapeutics
About this trial
The primary objective of the study is to evaluate the effect of MAR001 compared to placebo on levels of TG in adults with elevated TG and RC.
Eligibility criteria
Qualifiers
Elevated fasting TGs and RC
Elevated nonfasting TGs and RC
Part A only: Fasting LDL-C ≥ 50 mg/dL (≥ 1.29 mmol/L) and ≤ 130 mg/dL (≤ 3.36 mmol/L)
Willingness to provide informed consent and comply with the intervention and all study assessments
Disqualifiers
Acute or chronic liver disease
Part A only: TG concentration ≥880mg/dl; Part B only: TG concentration ≥2000 mg/dL
History of type 1 diabetes mellitus or history of diabetic ketoacidosis
Newly diagnosed T2DM
Trial design
Treatments tested in this trial
- MAR001
- Placebo
Treatment groups
316 Participants
are divided into 4 treatment groupsSponsors and collaborators
Marea Therapeutics
Lead sponsor
The TIMI Study Group
Collaborator
Source ClinicalTrials.gov